Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Top Cited Papers
- 28 April 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 16 (6), 425-434
- https://doi.org/10.1016/s1474-4422(17)30083-2
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- Defining the Differences Between Episodic Migraine and Chronic MigraineCurrent Pain and Headache Reports, 2011
- OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical ProgramHeadache: The Journal of Head and Face Pain, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Topiramate Treatment of Chronic Migraine: A Randomized, Placebo‐Controlled Trial of Quality of Life and Other Efficacy MeasuresHeadache: The Journal of Head and Face Pain, 2009
- Global prevalence of chronic migraine: A systematic reviewCephalalgia, 2009
- Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of LifeMayo Clinic Proceedings, 2009
- Medication–overuse headache: pathophysiological insightsThe Journal of Headache and Pain, 2005
- Vasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnnals of Neurology, 1990